Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

NCT01490047 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Solid Tumors
Lymphomas

Interventions

DRUG: Recombinant human TNF-α
DRUG: Liposomal doxorubicin
DRUG: Caelyx
DRUG: Recombinant human TNF-α

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]